AXIS Consulting has announced details of its forthcoming Market Access Masterclass which this year takes place as a virtual meeting held over two separate days, September 18th and 23rd 2020 from 9 am-12.15 pm. The AXIS Market Access Masterclass will review the reimbursement process for Orphan and Oncology medicines as well as submissions to BeNeLuxA and will integrate key insights from over 21 years of experience in Market Access in Ireland with important, relevant perspectives from a number of high-profile guest speakers.
Announcing the event Brenda Dooley, CEO, AXIS Consulting said, “This masterclass is an excellent opportunity to gain an in-depth, up to date understanding of the Irish reimbursement process. We will also be advising on how to avoid common submission pitfalls and we will share case studies on successful reimbursement applications in Ireland. Full details on our excellent speaker line up will be announced next week”.
Recognised as the leading knowledge broker on the Irish reimbursement pathway for many years with over 75+ completed submissions to the Irish authorities, AXIS Consulting provides a range of services to support reimbursement submissions in Ireland including local expert elicitation, systematic literature reviews, health technology assessments and evidence generation. Previous masterclass participants have attested to the valuable insights and high-quality content delivered.
“The AXIS team knew the Irish Market Access Landscape inside out – this is an essential masterclass to attend & I would thoroughly recommend it to other industry colleagues”. (Participant, AXIS Masterclass, March 2020).
The fee for attendance at the Market Access Masterclass on September 18th – 23rd is €495 inclusive of VAT. Bookings can now be made directly at https://axishealthcareconsulting.com/virtualmasterclass-sept/
AXIS Consulting is an Irish company formed in 2012 with registered offices in Baggot Street, Dublin and directly employs a team of health economists and statisticians with plans to expand the team further in the months ahead.
